Clinical Research Malaysia (CRM) – Dr. Mohamed Ali Abu Bakar, CEO
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
Address: 16th Floor, Plaza VADS, No.1, Jalan Tun Mohd. Fuad,
Taman Tun Dr. Ismail, 60000 Kuala Lumpur, Malaysia
Tel: 603-7727 6390
Web: http://www.yspsah.com/Home/Home.asp
Since its establishment YSP has grown to become one of the innovative and leading pharmaceutical companies in Malaysia. The Group became more competent and hence, in 2004 it gained successful listing on the Bursa Malaysia Securities Bhd ( Kuala Lumpur Stock Exchange ) and later transferred to the Main Board, which marked a major milestone in history. Today the Group boasts a wide array of pharmaceutical, over-the-counter (OTC), veterinary and aquatic products, with regional offices as well as strategic alliances in Singapore, Vietnam, Philippine, Myanmar, Cambodia, Thailand, Indonesia, Brunei, Laos , as well as Sri Lanka, Africa and countries in Middle East.
In addition, YSP have also diversified into traditional herbal products with Sun Ten Pharmaceutical Co. Ltd, a renowned GMP manufacturer of standardized and concentrated herbal extracts from Taiwan R.O.C.
YSP has expertise and capability in the production of gel, capsule, tablet, suppository, cream, syrup, suspension and powder dosage form. These include therapeutic group of antibiotics, antifungals, antacids, anti-diabetics, anti-platelets, antivirals, injectables and eye drops, in order to satisfy customers’ needs and enhance quality of life.
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here